Khan Najat
SEC CIK 2020969 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| RXRX | RECURSION PHARMACEUTICALS, INC. | Chief R, D Commercial Off, Dir | 2.07M | — | $1.01M | 17 | 2024-08-01 | 2026-09-08 |
Most active insiders at RXRX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Borgeson Blake | Dir | — | $4.10M |
| 2 | Gibson Christopher | Dir | — | $3.84M |
| 3 | Khan Najat | Chief R, D Commercial Off, Dir | — | $806.7K |
| 4 | Taylor Ben R | CFO | — | $157.7K |
| 5 | Bumpus Namandje | Dir | — | $28.1K |
| 6 | Michor Franziska | Dir | — | — |
| 7 | Hallett David | CSO | — | — |
| 8 | Dar Zavain | Dir | — | — |
| 9 | Li Dean Y | Dir | — | — |
| 10 | Sun Elaine D | Dir | — | — |
Transactions 17
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-09-10 17:55 | 2026-09-08 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | CEO, Pres, Dir | S - Sale | $3.52 | -22.4K | 2.07M | -1% | -$78.8K |
| 2026-08-18 17:44 | 2026-08-17 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | CEO, Pres, Dir | F - Tax | $3.16 | -80.5K | 2.10M | -4% | -$254.4K | |
| T | 2026-06-05 17:02 | 2026-06-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | CEO, Pres, Dir | S - Sale | $3.58 | -23.6K | 2.18M | -1% | -$84.5K |
| 2026-05-19 17:54 | 2026-05-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | CEO, Pres, Dir | F - Tax | $3.04 | -62.7K | 2.20M | -3% | -$190.6K | |
| 2026-03-11 | 2026-03-09 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | CEO, Pres, Dir | S - Sale | $3.35 | -28.3K | 2.26M | -1% | -$94.8K | |
| 2026-02-19 | 2026-02-17 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | CEO, Pres, Dir | F - Tax | $3.49 | -14.3K | 2.29M | -0.6% | -$49.8K | |
| M | 2026-02-10 | 2026-02-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | CEO, Pres, Dir | A - Grant | $0.00 | +1.70M | 2.28M | +293% | $0 |
| 2026-02-10 | 2026-02-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | CEO, Pres, Dir | F - Tax | $3.98 | -10.4K | 2.30M | -0.4% | -$41.2K | |
| 2025-12-29 | 2025-12-22 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | Chief R, D Commercial Off, Dir | S - Sale | $4.41 | -124.4K | 611.1K | -17% | -$548.6K | |
| 2025-11-19 | 2025-11-17 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | Chief R, D Commercial Off, Dir | F - Tax | $4.14 | -17.6K | 735.5K | -2% | -$72.8K | |
| D | 2025-11-06 | 2025-11-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | Chief R, D Commercial Off, Dir | A - Grant | $0.00 | +84.9K | 753.1K | +13% | $0 |
| 2025-08-19 | 2025-08-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | Chief R, D Commercial Off, Dir | F - Tax | $5.64 | -3,789 | 704.8K | -0.5% | -$21.4K | |
| 2025-08-19 | 2025-08-18 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | Chief R, D Commercial Off, Dir | S - Sale | $5.52 | -36.6K | 668.2K | -5% | -$202.0K | |
| 2025-05-19 | 2025-05-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | Chief R, D Commercial Off, Dir | F - Tax | $4.25 | -3,796 | 708.6K | -0.5% | -$16.1K | |
| D | 2025-02-05 | 2025-02-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | Chief R, D Commercial Off, Dir | F - Tax | $7.25 | -2,753 | 712.4K | -0.4% | -$20.0K |
| DM | 2025-02-05 | 2025-02-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | Chief R, D Commercial Off, Dir | A - Grant | $0.00 | +218.2K | 715.1K | +44% | $0 |
| D | 2024-08-05 | 2024-08-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | Chief R, D Commercial Off, Dir | A - Grant | $0.00 | +497.0K | 497.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations